Did Medtronic beat its earnings expectations this quarter?

Medtronic reported non-GAAP diluted EPS of $1.39, up 7% year over year, and management said this came in above the high end of its guidance range. GAAP diluted EPS was $1.01, up 2%. The beat was driven by margin improvement rather than a large revenue surprise, as organic growth of 4.1% was in line with the company's mid-single-digit trajectory.

Did Medtronic change its full-year guidance?

No. Medtronic reiterated its FY25 guidance, expecting organic revenue growth of 4.75% to 5% and non-GAAP diluted EPS of $5.44 to $5.50. Reported revenue growth including Other revenue and currency is expected at 3.4% to 3.8%, and the EPS guidance includes an estimated 5% currency headwind.

What is driving growth and what is lagging?

Pulsed field ablation drove Cardiac Ablation Solutions to low-20s growth, Neuromodulation grew 12.9% organically, and Diabetes grew 10.4%. Medical Surgical was the weak spot, declining 0.4% organically due to stapling market pressure, a transient change in U.S. distributor buying patterns, and a 30% year-over-year decline in U.S. respiratory hospitalizations that hurt Nellcor sales.

What does the renal denervation coverage decision mean for Medtronic?

CMS opened a National Coverage Analysis for renal denervation for treatment of hypertension and expects coverage to become final on or before October 11, 2025. Formal Medicare coverage could support adoption of Medtronic's renal denervation offering and expand its addressable market in cardiovascular, though the filing does not quantify the expected revenue impact.

How is Medtronic's balance sheet and capital allocation changing?

For the nine months, Medtronic generated free cash flow of $3.116B, up from $2.849B, but it repurchased $2.961B of ordinary shares and issued $3.209B of long-term debt. Current debt obligations rose to $2.622B from $1.092B at fiscal year-end, and dividends totaled $2.692B. Investors may want to watch how buybacks and debt issuance are balanced against free cash flow.

MDT 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 18, 2025. Cited figures are marked; the original filing is the authoritative source.

Medtronic plc reported third quarter fiscal 2025 results (quarter ended January 24, 2025) with worldwide revenue of $8.292 billion^a, up 2.5% as reported and 4.1% organic, marking the company's ninth consecutive quarter of mid-single-digit organic growth.

GAAP diluted EPS was $1.01^b (up 2%), while non-GAAP diluted EPS was $1.39 (up 7%), which management described as coming in above the high end of its guidance range. Gross margin expanded to 66.6% on a non-GAAP basis from 66.1%, and non-GAAP operating margin rose to 26.2% from 25.2%, indicating operating leverage on modest top-line growth. Growth was led by Cardiovascular (up 5.0% organic, with Cardiac Ablation Solutions up low-20s on pulsed field ablation products), Neuroscience (up 5.2% organic, with Neuromodulation up 12.9%), and Diabetes (up 10.4% organic).

Medical Surgical was flat-to-down (down 0.4% organic) due to stapling pressures and a transient U.S. distributor buying pattern change. Management reiterated FY25 guidance: organic revenue growth of 4.75% to 5% and non-GAAP diluted EPS of $5.44 to $5.50^c, which includes an estimated 5% currency headwind. Reported revenue growth including Other revenue and FX is expected at 3.4% to 3.8%.

The interim CFO, Gary Corona, said the company expects to accelerate both top- and bottom-line growth in Q4 and high-single-digit adjusted EPS growth in the second half of the fiscal year. The filing also disclosed a CMS National Coverage Analysis for renal denervation for hypertension, expected to be finalized by October 11, 2025, which could open a significant new market. For investors, the key items are the quality of the earnings beat, the margin expansion, and the reliance on a back-half acceleration to hit full-year targets.

Free cash flow for the nine months rose to $3.116 billion^d from $2.849 billion, but the company also repurchased $2.961 billion of shares and issued $3.2 billion of long-term debt during the period. Total debt rose and current debt obligations increased to $2.622 billion, which investors may want to monitor alongside the buyback pace.

02—Key points

Key Highlights

Q3 FY25 worldwide revenue of $8.292B grew 2.5% as reported and 4.1% organic, the ninth straight quarter of mid-single-digit organic growth.
Non-GAAP diluted EPS of $1.39 rose 7% and beat the high end of guidance; GAAP diluted EPS of $1.01 rose 2%.
Non-GAAP gross margin improved to 66.6% from 66.1%, and non-GAAP operating margin expanded to 26.2% from 25.2%.
Cardiac Ablation Solutions grew low-20s percent on pulsed field ablation (PulseSelect and Affera Sphere-9), and Micra transcatheter pacing grew mid-20s.
Diabetes revenue rose 10.4% organic and Neuromodulation grew 12.9% organic, while Medical Surgical declined 0.4% organic on stapling pressure and a transient distributor buying pattern change.
FY25 guidance was reiterated: 4.75%-5% organic revenue growth and non-GAAP EPS of $5.44-$5.50, with management guiding to high-single-digit adjusted EPS growth in the second half.
CMS opened a National Coverage Analysis for renal denervation for hypertension, with a final decision expected on or before October 11, 2025.

03—Questions

Frequently Asked Questions

Did Medtronic beat its earnings expectations this quarter?
Medtronic reported non-GAAP diluted EPS of $1.39, up 7% year over year, and management said this came in above the high end of its guidance range. GAAP diluted EPS was $1.01, up 2%. The beat was driven by margin improvement rather than a large revenue surprise, as organic growth of 4.1% was in line with the company's mid-single-digit trajectory.
Did Medtronic change its full-year guidance?
No. Medtronic reiterated its FY25 guidance, expecting organic revenue growth of 4.75% to 5% and non-GAAP diluted EPS of $5.44 to $5.50. Reported revenue growth including Other revenue and currency is expected at 3.4% to 3.8%, and the EPS guidance includes an estimated 5% currency headwind.
What is driving growth and what is lagging?
Pulsed field ablation drove Cardiac Ablation Solutions to low-20s growth, Neuromodulation grew 12.9% organically, and Diabetes grew 10.4%. Medical Surgical was the weak spot, declining 0.4% organically due to stapling market pressure, a transient change in U.S. distributor buying patterns, and a 30% year-over-year decline in U.S. respiratory hospitalizations that hurt Nellcor sales.
What does the renal denervation coverage decision mean for Medtronic?
CMS opened a National Coverage Analysis for renal denervation for treatment of hypertension and expects coverage to become final on or before October 11, 2025. Formal Medicare coverage could support adoption of Medtronic's renal denervation offering and expand its addressable market in cardiovascular, though the filing does not quantify the expected revenue impact.
How is Medtronic's balance sheet and capital allocation changing?
For the nine months, Medtronic generated free cash flow of $3.116B, up from $2.849B, but it repurchased $2.961B of ordinary shares and issued $3.209B of long-term debt. Current debt obligations rose to $2.622B from $1.092B at fiscal year-end, and dividends totaled $2.692B. Investors may want to watch how buybacks and debt issuance are balanced against free cash flow.

04—Continue

← View all 8-K filings